Table 1.

Summary of Demographics and Baseline Characteristics of 42 RA Patients.

		with depression	without depression	p
n		12	30
Age (years)		62 (50-72)	51 (40-63)	0.079*
Sex (female: male)		10:2	23:7	0.491**
Body mass index		21 (20-23)	21 (20-23)	0.606*
Smoking history (yes : no)		6:6	22:8	0.277**
bDMARD-naïve or switch		7:5	23:7	0.938**
Disease duration (years)		8.5 (3.5-24.3)	2 (0.90-6.3)	0.210*
Prednisolone dosage (mg/d)		1 (0-5)	0 (0-5)	0.581*
MTX dosage (mg/w)		9 (5.5-10)	9 (6.5-11.5)	0.541*
ESR (mm/H)		30 (11-54)	17 (8-43)	0.411*
CRP (mg/dL)		1.3 (0.31-3.7)	0.56 (0.2-1.5)	0.427*
Serum MMP-3 level (ng/mL)		151 (84-378)	114 (65-191)	0.316*
Serum OXT level (pg/mL)		76 (59-81)	74 (58-93)	0.796*
SDAI		24 (20-31)	20 (13-27)	0.035*
TJC		6 (4.75-12.75)	4 (3-6.75)	0.079*
SJC		2 (2-4)	3 (2-4)	0.362*
PtGA (VAS, mm)		64 (58.75-73.5)	54.5 (24.25-69.5)	0.094*
PGA (VAS, mm)		71 (41.25-76)	38 (22.5-74.25)	0.315*
HAQ-DI		0.8125 (0.125-1.625)	0.375 (0-0.75)	0.055*
HAM-D		10 (9-12.25)	3 (1-5)	0.000*
SF-36	PCS	31 (22-36) n=11	34 (23-42) n=29	0.671*
	MCS	48 (36-52) n=11	53 (48-55) n=29	0.101*
	RCS	37 (34-46) n=11	57 (35-62) n=29	0.214*

median (interquartile range). bDMARDs: biological disease-modifying antirheumatic drugs, MTX: methotrexate, ESR: erythrocyte sedimentation rate, MMP-3: matrix metalloproteinase-3, OXT: oxytocin, SDAI: simplified disease activity index, TJC: tender joint count, SJC: swollen joint count, PtGA: patient’s global assessment, PGA: physician’s global assessment, HAQ-DI: Health Assessment Questionnaire Disability Index, HAM-D: Hamilton Depression Rating Scale, SF-36: Short Form-36, PCS: physical component summary, MCS: mental component summary, RCS: role/social component summary, *analysis using a Mann-Whitney U test, **analysis using a chi-squared test for independence